{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:27:28Z","timestamp":1745468848808,"version":"3.40.4"},"reference-count":11,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T00:00:00Z","timestamp":1526515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T00:00:00Z","timestamp":1526515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Case Rep Oncol"],"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; Peritoneal carcinomatosis is usually a terminal disease with short median survival in patients with gastric cancer. Systemic FOLFOX is one of the most used regimens in the first-line treatment of metastatic gastric cancer. However, there is scarce evidence that cytoreductive surgery (CRS) and intraperitoneal heated chemotherapy (HIPEC) improves oncological outcomes of patients with advanced gastric cancer. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; Herein we present a case of a young woman with advanced gastric cancer with omental and peritoneal metastases who achieved an excellent response after 6 months of FOLFOX followed by CRS and HIPEC. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; A 53-year-old woman was diagnosed with advanced gastric carcinoma, with extensive omental caking and several peritoneal implants measuring 2 cm at the largest diameter. The patient received mFOLFOX6 for 6 months with excellent clinical and radiographic response. She was then submitted to a D2 total gastrectomy followed by CRS and HIPEC with mitomycin. The final pathology report showed a focal adenocarcinoma in the stomach measuring 0.4 mm with no residual tumor in the peritoneum (ypT1ypN0). The patient has been well and disease free for more than 4 years. &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; While still controversial, CRS followed by HIPEC may be a curative therapeutic option for highly selected patients.<\/jats:p>","DOI":"10.1159\/000488978","type":"journal-article","created":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T21:01:22Z","timestamp":1526590882000},"page":"305-310","source":"Crossref","is-referenced-by-count":2,"title":["Complete Response for More than 4 Years following Neoadjuvant FOLFOX and Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for a Patient with Advanced Gastric Cancer with Extensive Peritoneal Carcinomatosis"],"prefix":"10.1159","volume":"11","author":[{"given":"Renata\u00a0D\u2019Alpino","family":"Peixoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tercia\u00a0Tarciane","family":"de\u00a0Sousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro\u00a0Alexandre\u00a0Ismael\u00a0Amaral","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana\u00a0Rodrigues","family":"de\u00a0Meirelles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos\u00a0Henrique\u00a0Andrade","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2018,5,17]]},"reference":[{"doi-asserted-by":"publisher","key":"ref1","DOI":"10.1093\/ije\/29.4.645"},{"doi-asserted-by":"publisher","key":"ref2","DOI":"10.1016\/S1470-2045(04)01425-1"},{"doi-asserted-by":"publisher","key":"ref3","DOI":"10.1046\/j.1365-2168.2000.01358.x"},{"doi-asserted-by":"publisher","key":"ref4","DOI":"10.1097\/01.sla.0000143245.28656.15"},{"doi-asserted-by":"publisher","key":"ref5","DOI":"10.1002\/(SICI)1097-0142(19990201)85:3<529::AID-CNCR3>3.0.CO;2-9"},{"doi-asserted-by":"publisher","key":"ref6","DOI":"10.3109\/07357907.2012.654871"},{"doi-asserted-by":"publisher","key":"ref7","DOI":"10.1016\/j.ctrv.2016.06.007"},{"doi-asserted-by":"publisher","key":"ref8","DOI":"10.1002\/cncr.25356"},{"doi-asserted-by":"publisher","key":"ref9","DOI":"10.1245\/s10434-010-1039-7"},{"doi-asserted-by":"publisher","key":"ref10","DOI":"10.1245\/s10434-011-1631-5"},{"doi-asserted-by":"publisher","key":"ref11","DOI":"10.1002\/jso.23633"}],"container-title":["Case Reports in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/488978","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/488978","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:24:45Z","timestamp":1745425485000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000488978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,17]]},"references-count":11,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,12,20]]},"published-print":{"date-parts":[[2018,8,31]]}},"URL":"https:\/\/doi.org\/10.1159\/000488978","archive":["Portico"],"relation":{},"ISSN":["1662-6575"],"issn-type":[{"type":"electronic","value":"1662-6575"}],"subject":[],"published":{"date-parts":[[2018,5,17]]}}}